Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics,…